Navigation Links
Saladax Biomedical, Inc. Announces European Commercialization Team
Date:5/2/2011

BETHLEHEM, Pa., OBERWIL, Switzerland and MUNICH, May 2, 2011 /PRNewswire/ -- Saladax Biomedical, Inc., a privately held company developing and commercializing novel diagnostic assays to achieve the promise of personalized medicine for new and existing therapeutics, announced today the formation of its European commercialization team to expand its European presence.

Reporting to Adrienne Choma, Esq., Saladax VP, Marketing and Sales, members of Saladax's European commercialization team include:

  • Ursula Sonnenschein, Ph.D. (Sonnenscheinbiotec GmbH) -- Dr. Sonnenschein is founder of Sonnenscheinbiotec GmbH in Switzerland, a company offering consulting and market development services for in-vitro diagnostics.  She will lead Saladax's efforts in German-speaking markets by leveraging her extensive experience to oversee sales of My5-FU®.  Dr. Sonnenschein was formerly international marketing and sales manager at Buhlmann Laboratories AG, a Swiss diagnostic company.  Prior to Buhlmann, as director of operations at Pharmacia Diagnostics, she was responsible for production and quality control of the company's autoimmunity division.  Before Pharmacia, she managed the assay development department for Elias GmbH&CoKG, a company focusing on the diagnosis of autoimmune diseases.

  • Paul Kenny (KKPD GbR) -- Mr. Kenny, who has significant knowledge of clinical biochemistry and the clinical laboratory environment, will be involved in Saladax's European sales and scientific support.  As founder and managing partner at KKPD GbR, Mr. Kenny works with multiple diagnostic companies to develop and expand their European presence by aiding in all aspects of the business, including market research, regulatory compliance, specification development, sales and support.  Previously, Mr. Kenny was global product manager at Olympus Life and Material Sciences Europe GmbH, where he helped launch the AU3000i immunoassay system, a highly advanced, automated in vitro diagnostic system.  Mr. Kenny led a global launch team, providing clinical, scientific and market input for the project, and developed documentation and promotional materials.  Mr. Kenny started his career as manager of a clinical biochemistry laboratory in the UK before moving into the IVD industry and has held numerous positions within multiple diagnostic companies throughout Europe.

  • Janine Dias (KKPD GbR) -- Ms. Dias will be responsible for technical and scientific support for Saladax's European customers and will facilitate clinical studies and performance evaluations of Saladax's products in Europe.  As managing partner of KKPD GbR, Ms. Dias supports KKPD's clients with execution of European market entry strategy, including technical and scientific marketing and sales activities, planning and execution of product evaluations and generation of scientific and sales-oriented product documentation.  Before KKPD, Ms. Dias was product manager and member of Olympus Life Science Research Europa GmbH's Global Product Marketing group where she was responsible for global marketing activities for the AU3000i immunoassay system.

"Given their extensive industry experience, we are confident the European commercialization team we've assembled will successfully lead our growing marketing efforts in Europe," said Edward L. Erickson, president and CEO of Saladax.  "Dr. Sonnenschein, Mr. Kenny and Ms. Dias have proven track records that will allow Saladax to broaden its sales and marketing efforts of My5FU®, the first of the company's innovative dose management assays commercially available."

About Saladax Biomedical, Inc.

Saladax Biomedical develops and commercializes novel diagnostic assays to achieve the promise of personalized medicine through dose management and companion diagnostic products for existing and new therapeutics.  Founded in 2004 and based in Bethlehem, PA, the Company's dose management technology enables physicians to optimize the dose of drugs to meet individual patient needs, thus leading to improved response and quality of life.  The Company's portfolio of 15 MyCare™ dose management assays is comprised of proprietary, automated and cost-effective in vitro diagnostic tests in various stages of development, with a principal focus in oncology.  The first MyCare assay available is for one of the most common anticancer drugs, 5-fluorouracil (5-FU).  This assay is available in the United States from Myriad Genetics under the trade name OnDose®, sold by Saladax in Europe with CE Mark clearance as My5-FU® and will be distributed in Japan exclusively by FALCO biosystems.  Saladax also works with pharmaceutical companies to develop companion diagnostics to provide important clinical information to assist in the development and administration of new and existing compounds.  

Saladax Biomedical, Inc.
Adrienne Choma, Esq.
VP Marketing & Sales
achoma@saladax.com

Media Contact:
Tiberend Strategic Advisors, Inc.
212-827-0020
Andrew Mielach
amielach@tiberend.com


'/>"/>
SOURCE Saladax Biomedical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Bio-Matrix Scientific Group, Inc. Announces Preferred Stock Dividend and Spinoff of Wholly-Owned Subsidiary, Entest Biomedical, Inc.
2. ArunA Biomedical, Inc. Announces Alliance with Neuromics for Distribution of Normal Human Neural Cells
3. Balan Biomedical, Inc. Announces the Formation of Battery Consulting Group
4. ERT Announces Appointment of New President and CEO
5. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2011 Financial Results
6. Keryx Biopharmaceuticals Announces Positive Final Data from Zerenex™ Short-Term Phase 3 Study
7. Vestaron Corporation Announces New Leadership
8. CBI Announces Partnership With Childrens Rare Disease Network and The Global Genes Project
9. Sequenom Announces Publication Acceptance of Manuscript From Age-related Macular Degeneration Validation Study
10. China Green Material Technologies, Inc. Announces Change of Auditor to Marcum Bernstein & Pinchuk LLP
11. Talecris Biotherapeutics Announces First Quarter 2011 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... ... March 30, 2017 , ... ... four posters at the American Association for Cancer Research (AACR) Annual Meeting ... of Vortex’s technology to rapidly collect highly enriched populations of CTCs, undamaged by ...
(Date:3/29/2017)... ... March 29, 2017 , ... Zansors announced today ... as issued by the U.S. Patent & Trademark Office (USPTO). The patent covers ... and health monitoring. This invention will be critical to the future of wearable ...
(Date:3/29/2017)... -- "Surging application of gesture control features in automobiles ... to drive the growth of gesture recognition and touchless ... expected to be worth USD 18.98 billion by 2022, ... 2022. The touchless sensing market is expected to be ... CAGR of 17.44% between 2017 and 2022. Gesture recognition ...
(Date:3/29/2017)... Palo Alto, CA, USA (PRWEB) , ... March 29, 2017 , ... ... experts in various regulatory subjects has announced its 3rd Annual Medical Device Summit 2017 ... 2017 at the Omni Parker House Hotel, in Boston, MA. , The Omni Parker ...
Breaking Biology Technology:
(Date:2/26/2017)... DALLAS , Feb. 25, 2017  Securus ... justice technology solutions for public safety, investigation, corrections ... of Recidivism and Reentry. "Too often, ... State prisons and county jails are trying to ... of inmates and friends and family members. While significant ...
(Date:2/22/2017)... , Feb. 22, 2017 With ... 2021, ABI Research identifies four technologies that innovative ... to secure significant share in the changing competitive ... and passive authentication.   "Companies can ... comes to security," says Dimitrios Pavlakis , ...
(Date:2/21/2017)... , February 21, 2017 ... 70 Millionen US-Dollar wachsen. Nach einem Gespräch mit mehr als ... einige Hindernisse zu überwinden gilt, um diese Prognose zu ... ... anderem die Mobilisierung der finanziellen Mittel für die Biobank, ...
Breaking Biology News(10 mins):